[Clinical manifestations and effects of IVGG in patients with Kawasaki disease]
- PMID: 8709183
[Clinical manifestations and effects of IVGG in patients with Kawasaki disease]
Abstract
From Jan 1984 till Dec 1992, 293 patients--180 males and 113 females (M:F = 1.5:1)--with Kawasaki disease visited the Pediatric Department of Kaohsiung Medical College Hospital. The mean age from the total cases were 28.5 months (2 months-10 years). Fever was the most common clinical symptom, followed by dry cracked lips (93.5%), pharyngeal injection (92.8%) and conjunctivitis (90.5%). Only 62.6% of the total cases had cervical lymph node swelling of which the prevalence was higher than the previous report of the National Taiwan University Hospital in 1985. Two hundred and ninety-three cases were divided randomly into 3 groups according to the different treatment regimens. The first group of 199 cases whose coronary artery change occurred in 85 cases (42.7%), were treated with aspirin alone. The second group of 80 cases were treated with aspirin and IVGG 400 mg/kg/day for 5 consecutive days. The prevalence of coronary artery abnormalities was 22.5% (18/80). The third group of 14 cases were treated with aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours. Coronary artery abnormalities occurred in 3 cases (21.4%). IVGG, initiated within 10 days of the onset of fever, in conjunction with aspirin decreased the prevalence of coronary artery dilatation and aneurysms significantly in comparison with treatment by the aspirin alone (p < 0.05). However, there was no difference in the prevalence of coronary aneurysm between the groups of single high dose and multiple doses, though the single high dose of IVGG can improve the clinical symptoms quickly and shorten the duration of hospitalization.
Similar articles
-
[Study on coronary artery lesions in patients with Kawasaki disease: recent 9 years' experience].Gaoxiong Yi Xue Ke Xue Za Zhi. 1993 Jan;9(1):27-38. Gaoxiong Yi Xue Ke Xue Za Zhi. 1993. PMID: 7682261 Clinical Trial. Chinese.
-
Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.J Pediatr. 1997 Dec;131(6):888-93. doi: 10.1016/s0022-3476(97)70038-6. J Pediatr. 1997. PMID: 9427895
-
Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.Pediatr Infect Dis J. 1993 Jun;12(6):509-12. doi: 10.1097/00006454-199306000-00010. Pediatr Infect Dis J. 1993. PMID: 8345983 Clinical Trial.
-
Overview of pharmacological treatment of Kawasaki disease.Drugs. 1999 Nov;58(5):813-22. doi: 10.2165/00003495-199958050-00004. Drugs. 1999. PMID: 10595862 Review.
-
Kawasaki syndrome.Clin Microbiol Rev. 1998 Jul;11(3):405-14. doi: 10.1128/CMR.11.3.405. Clin Microbiol Rev. 1998. PMID: 9665974 Free PMC article. Review.
Cited by
-
Salicylate for the treatment of Kawasaki disease in children.Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD004175. doi: 10.1002/14651858.CD004175.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054199 Free PMC article.
-
The profiles of Kawasaki disease in China.J Epidemiol. 2001 May;11(3):103-8. doi: 10.2188/jea.11.103. J Epidemiol. 2001. PMID: 11434420 Free PMC article.
-
Intravenous immunoglobulin for the treatment of Kawasaki disease in children.Cochrane Database Syst Rev. 2003;2003(4):CD004000. doi: 10.1002/14651858.CD004000. Cochrane Database Syst Rev. 2003. PMID: 14584002 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials